ARTICLE | Clinical News
Naloxone regulatory update
December 13, 2010 8:00 AM UTC
FDA granted Orphan Drug designation for Elorac's naloxone lotion for the topical treatment of pruritus accompanying cutaneous T cell lymphoma (CTCL). The opiate antagonist is slated to begin Phase III...